Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $33 to $32.
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $33 to $32.